IL18 and type 2 diabetes mellitus: No changes were noted in IL-18.<h4>Conclusion</h4>Imeglimin, especially in combination with non-Metformin OHAs, improves glycemic control and reduces mitochondrial and inflammatory stress in T2DM patients.